LOS ANGELES, CA – February 18, 2026 (NEWMEDIAWIRE) – LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who previously facilitated LIXTE’s November 2025 acquisition of Liora’s assets, brings more than 20 years of healthcare operational and strategic advisory experience and will lead advancement of Liora’s LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Management declared the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.
To view the full press release, visit https://ibn.fm/9kbfE
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focutilized on new tarreceives for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Please see full terms of utilize and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Forward Looking Statements
Certain statements in this article are forward-viewing, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cautilize actual results to differ materially from the information expressed or implied by these forward-viewing statements and may not be indicative of future results. These forward-viewing statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the Company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the Company’s Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. Undue reliance should not be placed on the forward-viewing statements in this article in creating an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
View the original release on www.newmediawire.com
Leave a Reply